Compare MAGN & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MAGN | COCH |
|---|---|---|
| Founded | 1864 | 1995 |
| Country | United States | United States |
| Employees | 8500 | 47 |
| Industry | Paper | Blank Checks |
| Sector | Basic Materials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 437.2M | 49.7M |
| IPO Year | N/A | N/A |
| Metric | MAGN | COCH |
|---|---|---|
| Price | $12.41 | $0.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | $6.00 |
| AVG Volume (30 Days) | 326.6K | ★ 691.4K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.37 | $1.58 |
| Revenue Next Year | $3.47 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.82 | $0.36 |
| 52 Week High | $15.52 | $1.89 |
| Indicator | MAGN | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 60.24 |
| Support Level | $9.73 | $0.64 |
| Resistance Level | $12.96 | $0.90 |
| Average True Range (ATR) | 0.58 | 0.07 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 73.75 | 46.95 |
Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.